FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205549327> ?p ?o ?g. }

• W4205549327 abstract "A variety of minimally invasive treatments are available as an alternative to transurethral resection of the prostate (TURP) for management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). However, it is unclear which treatments provide better results.Our primary objective was to assess the comparative effectiveness of minimally invasive treatments for lower urinary tract symptoms in men with BPH through a network meta-analysis. Our secondary objective was to obtain an estimate of relative ranking of these minimally invasive treatments, according to their effects.We performed a comprehensive search of multiple databases (CENTRAL, MEDLINE, Embase, Scopus, Web of Science and LILACS), trials registries, other sources of grey literature, and conference proceedings, up to 24 February 2021. We had no restrictions on language of publication or publication status.We included parallel-group randomized controlled trials assessing the effects of the following minimally invasive treatments, compared to TURP or sham treatment, on men with moderate to severe LUTS due to BPH: convective radiofrequency water vapor therapy (CRFWVT); prostatic arterial embolization (PAE); prostatic urethral lift (PUL); temporary implantable nitinol device (TIND); and transurethral microwave thermotherapy (TUMT).Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model for pair-wise comparisons and a frequentist network meta-analysis for combined estimates. We interpreted them according to Cochrane methods. We planned subgroup analyses by age, prostate volume, and severity of baseline symptoms. We used risk ratios (RRs) with 95% confidence intervals (CIs) to express dichotomous data and mean differences (MDs) with 95% CIs to express continuous data. We used the GRADE approach to rate the certainty of evidence.We included 27 trials involving 3017 men, mostly over age 50, with severe LUTS due to BPH. The overall certainty of evidence was low to very low due to concerns regarding bias, imprecision, inconsistency (heterogeneity), and incoherence. Based on the network meta-analysis, results for our main outcomes were as follows. Urologic symptoms (19 studies, 1847 participants): PUL and PAE may result in little to no difference in urologic symptoms scores (MD of International Prostate Symptoms Score [IPSS]) compared to TURP (3 to 12 months; MD range 0 to 35; higher scores indicate worse symptoms; PUL: 1.47, 95% CI -4.00 to 6.93; PAE: 1.55, 95% CI -1.23 to 4.33; low-certainty evidence). CRFWVT, TUMT, and TIND may result in worse urologic symptoms scores compared to TURP at short-term follow-up, but the CIs include little to no difference (CRFWVT: 3.6, 95% CI -4.25 to 11.46; TUMT: 3.98, 95% CI 0.85 to 7.10; TIND: 7.5, 95% CI -0.68 to 15.69; low-certainty evidence). Quality of life (QoL) (13 studies, 1459 participants): All interventions may result in little to no difference in the QoL scores, compared to TURP (3 to 12 months; MD of IPSS-QoL score; MD range 0 to 6; higher scores indicate worse symptoms; PUL: 0.06, 95% CI -1.17 to 1.30; PAE: 0.09, 95% CI -0.57 to 0.75; CRFWVT: 0.37, 95% CI -1.45 to 2.20; TUMT: 0.65, 95% CI -0.48 to 1.78; TIND: 0.87, 95% CI -1.04 to 2.79; low-certainty evidence). Major adverse events (15 studies, 1573 participants): TUMT probably results in a large reduction of major adverse events compared to TURP (RR 0.20, 95% CI 0.09 to 0.43; moderate-certainty evidence). PUL, CRFWVT, TIND and PAE may also result in a large reduction in major adverse events, but CIs include substantial benefits and harms at three months to 36 months; PUL: RR 0.30, 95% CI 0.04 to 2.22; CRFWVT: RR 0.37, 95% CI 0.01 to 18.62; TIND: RR 0.52, 95% CI 0.01 to 24.46; PAE: RR 0.65, 95% CI 0.25 to 1.68; low-certainty evidence). Retreatment (10 studies, 799 participants): We are uncertain about the effects of PAE and PUL on retreatment compared to TURP (12 to 60 months; PUL: RR 2.39, 95% CI 0.51 to 11.1; PAE: RR 4.39, 95% CI 1.25 to 15.44; very low-certainty evidence). TUMT may result in higher retreatment rates (RR 9.71, 95% CI 2.35 to 40.13; low-certainty evidence). Erectile function (six studies, 640 participants): We are very uncertain of the effects of minimally invasive treatments on erectile function (MD of International Index of Erectile Function [IIEF-5]; range 5 to 25; higher scores indicates better function; CRFWVT: 6.49, 95% CI -8.13 to 21.12; TIND: 5.19, 95% CI -9.36 to 19.74; PUL: 3.00, 95% CI -5.45 to 11.44; PAE: -0.03, 95% CI -6.38, 6.32; very low-certainty evidence). Ejaculatory dysfunction (eight studies, 461 participants): We are uncertain of the effects of PUL, PAE and TUMT on ejaculatory dysfunction compared to TURP (3 to 12 months; PUL: RR 0.05, 95 % CI 0.00 to 1.06; PAE: RR 0.35, 95% CI 0.13 to 0.92; TUMT: RR 0.34, 95% CI 0.17 to 0.68; low-certainty evidence). TURP is the reference treatment with the highest likelihood of being the most efficacious for urinary symptoms, QoL and retreatment, but the least favorable in terms of major adverse events, erectile function and ejaculatory function. Among minimally invasive procedures, PUL and PAE have the highest likelihood of being the most efficacious for urinary symptoms and QoL, TUMT for major adverse events, PUL for retreatment, CRFWVT and TIND for erectile function and PUL for ejaculatory function.Minimally invasive treatments may result in similar or worse effects concerning urinary symptoms and QoL compared to TURP at short-term follow-up. They may result in fewer major adverse events, especially in the case of PUL and PAE; resulting in better rankings for symptoms scores. PUL may result in fewer retreatments compared to other interventions, especially TUMT, which had the highest retreatment rates at long-term follow-up. We are very uncertain about the effects of these interventions on erectile function. There was limited long-term data, especially for CRFWVT and TIND. Future high-quality studies with more extended follow-up, comparing different, active treatment modalities, and adequately reporting critical outcomes relevant to patients, including those related to sexual function, could provide more information on the relative effectiveness of these interventions." @default.
• W4205549327 created "2022-01-25" @default.
• W4205549327 creator A5001861927 @default.
• W4205549327 creator A5010356284 @default.
• W4205549327 creator A5013203178 @default.
• W4205549327 creator A5014757964 @default.
• W4205549327 creator A5025849789 @default.
• W4205549327 creator A5036514742 @default.
• W4205549327 creator A5038162951 @default.
• W4205549327 creator A5044107299 @default.
• W4205549327 creator A5068789622 @default.
• W4205549327 creator A5077678731 @default.
• W4205549327 creator A5078001562 @default.
• W4205549327 date "2021-07-15" @default.
• W4205549327 modified "2023-10-16" @default.
• W4205549327 title "Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis" @default.
• W4205549327 cites W104808469 @default.
• W4205549327 cites W1491256997 @default.
• W4205549327 cites W149153818 @default.
• W4205549327 cites W1521556231 @default.
• W4205549327 cites W1583848026 @default.
• W4205549327 cites W1712984123 @default.
• W4205549327 cites W1796387324 @default.
• W4205549327 cites W1833872980 @default.
• W4205549327 cites W1857205340 @default.
• W4205549327 cites W1890241494 @default.
• W4205549327 cites W1927668539 @default.
• W4205549327 cites W1942438727 @default.
• W4205549327 cites W1966673975 @default.
• W4205549327 cites W1967385770 @default.
• W4205549327 cites W1968860914 @default.
• W4205549327 cites W1970733297 @default.
• W4205549327 cites W1973551357 @default.
• W4205549327 cites W1973914781 @default.
• W4205549327 cites W1975193560 @default.
• W4205549327 cites W1979702815 @default.
• W4205549327 cites W1979837745 @default.
• W4205549327 cites W1985493799 @default.
• W4205549327 cites W1987730025 @default.
• W4205549327 cites W1988953530 @default.
• W4205549327 cites W1989764900 @default.
• W4205549327 cites W1991247706 @default.
• W4205549327 cites W1992327579 @default.
• W4205549327 cites W1992683171 @default.
• W4205549327 cites W1995525708 @default.
• W4205549327 cites W1995840063 @default.
• W4205549327 cites W1996031076 @default.
• W4205549327 cites W1999118955 @default.
• W4205549327 cites W2000407739 @default.
• W4205549327 cites W2001432092 @default.
• W4205549327 cites W2002004951 @default.
• W4205549327 cites W2002580527 @default.
• W4205549327 cites W2004474087 @default.
• W4205549327 cites W2005687876 @default.
• W4205549327 cites W2009567938 @default.
• W4205549327 cites W2010699829 @default.
• W4205549327 cites W2020251526 @default.
• W4205549327 cites W2020568537 @default.
• W4205549327 cites W2021505568 @default.
• W4205549327 cites W2021724028 @default.
• W4205549327 cites W2024739089 @default.
• W4205549327 cites W2030556203 @default.
• W4205549327 cites W2030558854 @default.
• W4205549327 cites W2031543780 @default.
• W4205549327 cites W2034141166 @default.
• W4205549327 cites W2036509876 @default.
• W4205549327 cites W2037171825 @default.
• W4205549327 cites W2037593179 @default.
• W4205549327 cites W2040557955 @default.
• W4205549327 cites W2043014191 @default.
• W4205549327 cites W2050440257 @default.
• W4205549327 cites W2050675379 @default.
• W4205549327 cites W2051357816 @default.
• W4205549327 cites W2051495596 @default.
• W4205549327 cites W2053766817 @default.
• W4205549327 cites W2059733087 @default.
• W4205549327 cites W2060514542 @default.
• W4205549327 cites W2062527664 @default.
• W4205549327 cites W2063280565 @default.
• W4205549327 cites W2068706053 @default.
• W4205549327 cites W2070978869 @default.
• W4205549327 cites W2072374001 @default.
• W4205549327 cites W2074147400 @default.
• W4205549327 cites W2074533135 @default.
• W4205549327 cites W2085582807 @default.
• W4205549327 cites W2086240335 @default.
• W4205549327 cites W2086243966 @default.
• W4205549327 cites W2086561958 @default.
• W4205549327 cites W2090132603 @default.
• W4205549327 cites W2091808438 @default.
• W4205549327 cites W2094244210 @default.
• W4205549327 cites W2096883889 @default.
• W4205549327 cites W2096998881 @default.
• W4205549327 cites W2097319938 @default.
• W4205549327 cites W2099286969 @default.
• W4205549327 cites W2105669432 @default.
• W4205549327 cites W2106355635 @default.
• W4205549327 cites W2106455438 @default.
• W4205549327 cites W2106677608 @default.
• W4205549327 cites W2108116635 @default.

• next